ACHN News Alert Achillion Pharmaceuticals (ACHN) 13.28 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 6:49 AM

Achillion Pharmaceuticals (ACHN) 13.28 $ACHN

Sovaldi Can't Sustain The Current Prices Of Gilead Sciences' Stock: Algorithmic And Fundamental Analysis
I Know First Research - at Seeking Alpha - Fri Dec 12, 2:27PM CST

GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93)

Why Gilead Sciences and AbbVie Care About This Tiny Company
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 11, 9:18AM CST
Source: Gilead Sciences via Google Maps. Investors are focusing on AbbVie 's hepatitis C drug and its potential impact on Gilead Sciences ' hepatitis C market share if it wins FDA approval later this month. However, they might also want to keep...
VRTX: 118.55 (-2.23), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), ABBV: 65.27 (-1.76)

January 2015 Options Now Available For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Thu Dec 04, 11:03AM CST
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the January 2015 expiration.
ACHN: 13.28 (-0.11)

Critical Alerts For Achillion Pharmaceuticals, Linn Energy, Sears Holdings, Baidu and Qualcomm Released By InvestorsObserver
PR Newswire - Mon Dec 01, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ACHN, LINE, SHLD, BIDU and QCOM.
BIDU: 229.32 (+0.09), ACHN: 13.28 (-0.11), QCOM: 70.58 (-1.41), LINE: 12.01 (-1.32), SHLD: 32.30 (+0.15)

5 Stock-Moving Medtech Events This December
at Investor's Business Daily - Fri Nov 28, 1:18PM CST
December is usually a quiet month for medical tech news, but this year will bring a few potentially stock-moving events worth keeping an eye on. As you digest your Thanksgiving turkey, here are the top five in chronological order: By Dec. 5, biotech...
SNN: 32.48 (-0.41), ESRX: 82.88 (-1.10), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), PFE: 30.95 (-0.70), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), INCY: 74.65 (-1.27), EW: 128.87 (-3.20), ABBV: 65.27 (-1.76), ENTA: 43.23 (-3.20), SYK: 92.00 (-1.41), NVS: 93.52 (-0.82)

December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey
at The Street - Wed Nov 26, 5:00AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.
BLUE: 91.28 (+5.16), OREX: 5.74 (-0.02), BCRX: 10.06 (+0.02), ALNY: 100.45 (+0.23), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), INCY: 74.65 (-1.27), EPZM: 18.35 (-1.45), AGIO: 119.56 (+0.36), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)

Achillion to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue Nov 25, 5:04AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at two upcoming investor conferences:
ACHN: 13.28 (-0.11), DB: 30.78 (-0.56)

European Ad Comm gives thumbs up to AbbVie's HCV combo
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:48AM CST

GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)

Regulus To See Further Declines
Richard Pearson - Seeking Alpha - Wed Nov 19, 9:30AM CST
On October 22nd, Regulus Therapeutics (NASDAQ: RGLS ) released its " proof of concept " data for its Hep C drug RG-101. The stock price quickly soared from its prior level of $6-7 to as high as $25 (intra day) as enthusiasm for the drug ran...
ISIS: 62.32 (+0.45), ALNY: 100.45 (+0.23), ACHN: 13.28 (-0.11), RGLS: 16.06 (-0.25)

Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 259.00 (-4.00), QLTI: 3.52 (-0.02), VRX: 138.71 (-0.18), AGN: 208.47 (-2.67), SHPG: 213.70 (-0.41), AUXL: 33.11 (-0.72), ABBV: 65.27 (-1.76), SNY: 45.16 (-1.05), ABT: 43.69 (-0.77), ENDP: 68.77 (-2.45), AKRX: 41.24 (+0.38), PFE: 30.95 (-0.70), INCY: 74.65 (-1.27), SLXP: 103.36 (-2.79), MYL: 53.32 (-1.39), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), ICPT: 137.69 (-2.48), TEVA: 55.92 (-0.92), NVS: 93.52 (-0.82)

Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 259.00 (-4.00), QLTI: 3.52 (-0.02), VRX: 138.71 (-0.18), AGN: 208.47 (-2.67), SHPG: 213.70 (-0.41), AUXL: 33.11 (-0.72), ABBV: 65.27 (-1.76), SNY: 45.16 (-1.05), ABT: 43.69 (-0.77), ENDP: 68.77 (-2.45), AKRX: 41.24 (+0.38), PFE: 30.95 (-0.70), INCY: 74.65 (-1.27), SLXP: 103.36 (-2.79), MYL: 53.32 (-1.39), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), ICPT: 137.69 (-2.48), TEVA: 55.92 (-0.92), NVS: 93.52 (-0.82)

Nasdaq stocks posting largest percentage increases
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ESCA: 13.78 (-0.11), IMDZ: 22.35 (-0.20), OLED: 26.61 (-0.25), FUEL: 14.85 (+0.89), CZR: 12.83 (-2.03), NTIC: 21.00 (-0.41), RESN: 9.01 (-0.10), OREX: 5.74 (-0.02), VBFC: 22.76 (+0.01), FLML: 16.83 (+0.28), ACHN: 13.28 (-0.11), RDI: 12.59 (unch), AMOT: 20.77 (-1.16), SUSQ: 13.06 (-0.19), RDIB: 12.88 (+0.52)

Profit taking sinks Achillion
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 12:48PM CST

ACHN: 13.28 (-0.11)

5 Momentum Stocks Currently on the Move with More Potential Upside
at The Street - Thu Nov 13, 11:34AM CST
Achillion, Groupon, Orexigen, Rackspace and TG Therapeutics have had strong recent moves and are showing no sign of slowing.
OREX: 5.74 (-0.02), RAX: 45.39 (-0.86), ACHN: 13.28 (-0.11), TGTX: 18.25 (+0.74), GRPN: 7.22 (-0.04)

Will Achillion Pharmaceuticals (ACHN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:25AM CST
Will Achillion Pharmaceuticals (ACHN) Continue to Surge Higher?
ACHN: 13.28 (-0.11)

Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), ABBV: 65.27 (-1.76)

Achillion Pharmaceuticals (ACHN) Stock Rises on Positive Hepatitis C Drug Results
at The Street - Wed Nov 12, 10:57AM CST
Shares of Achillion Pharmaceuticals (ACHN) continued to rise Wednesday after the company reported encouraging interim results from a Phase II study of its hepatitis C drug ACH-3102.
ACHN: 13.28 (-0.11)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 118.55 (-2.23), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), DNDN: 0.13 (-0.02), AMGN: 164.53 (-1.55), ABBV: 65.27 (-1.76), REGN: 416.44 (-7.91)

This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 7:43AM CST
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Beef 'O' Brady's Expands Into Tuscaloosa Market

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Employment Law Suit Hits ABC: Alleged Wage Violations

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...